Short-term effects of biocorrodible iron stents in porcine coronary arteries

Journal of Interventional Cardiology

Volumn 21, Issue 1, 2008, Pages 15-20

  Waksman, Ron ^a   Pakala, Rajbabu ^a   Baffour, Richard ^a   Seabron, Rufus ^a   Hellinga, David ^a   Tio, Fermin O ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; COBALT; FIBRIN; IRON;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; CORONARY ARTERY; HISTOCHEMISTRY; INFLAMMATION; INTIMA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; STENT; SWINE; THROMBOSIS;

ANIMALS; BIOCOMPATIBLE MATERIALS; CHROMIUM; COBALT; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; CORONARY VESSELS; FIBRIN; INFLAMMATION; IRON COMPOUNDS; STENTS; SWINE;

EID: 38749145234     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00319.x     Document Type: Article

References (23)

1. Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987 316 : 701 706.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003 349 : 1315 1323.
3. Bayes-Genis A, Camrud AR, Jorgenson M, et al. Pressure rinsing of coronary stents immediately before implantation reduces inflammation and neointimal hyperplasia. J Am Coll Cardiol 2001 38 : 562 568.
4. Konig A, Schiele TM, Rieber J, et al. Influence of stent design and deployment technique on neointima formation and vascular remodeling. Z Kardiol 2002 91 Suppl 3 98 102.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006 48 : 193 202.
6. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005 112 : 270 278.
7. Guagliumi G, Virmani R, Musumeci G, et al. Drug-eluting versus bare metal coronary stents: Long-term human pathology: Findings from different coronary arteries in the same patient. Ital Heart J 2003 4 : 713 720.
8. Dawkins KD, Grube E, Guagliumi G, et al. TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: Support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005 112 : 3306 3313.
9. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al., for the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting versus bare-metal stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006 48 : 2584 2591.
10. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007 297 : 209 211.
11. Tsuji T, Tamai H, Igaki K, et al. Biodegradable stents as a platform to drug loading. Int J Cardiovasc Intervent 2003 5 : 13 16.
12. Yamawaki T, Shimokawa H, Kozai T, et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998 32 : 780 786.
13. Vogt F, Stein A, Rettemeier G, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary poly-lactide stent. Eur Heart J 2004 25 : 1330 1340.
14. Hietala EM, Salminen US, Stahls A, et al. Biodegradation of the copolymeric polylactide stent: Long-term follow-up in a rabbit aorta model. J Vasc Res 2001 38 : 361 369.
15. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000 102 : 399 404.
16. van der Giessen W, Lincoff M, Schwartz R, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996 94 : 1690 1697.
17. Heublein B, Rohde R, Kaese V, et al. Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology? Heart 2003 89 : 651 656.
18. Waksman R, Pakala R, Kuchulakanti PK, et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006 68 : 607 617.
19. Peuster M, Wohlsein P, Brugmann M, et al. A novel approach to temporary stenting: Degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart 2001 86 : 563 569.
20. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J. Am. Coll Cardiol 1992 19 : 267 274.
21. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999 341 : 1986 1995.
22. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998 31 : 81 86.
23. Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988 111 : 566 570.